🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06911697
Recruiting Not applicable

Study on c-Met Targeted PET/CT Imaging in NSCLC

NCT06911697 · tracked via the Priya Life Science China tracker
Sponsor
Xilin Sun
Phase
Not applicable
Started
2023-10-26
Last updated
2025-04-04

Condition(s) studied

PET/CT ImagingNSCLC

Investigational drug(s) / intervention(s)

18F-TSPF PET/CT

18F-TSPF PET/CT: Each subject receives interval imaging of 18F-TSPF PET/CT and 18F-FDG PET/CT, and further follow-up.

Study summary

The investigators developed a 18F labeled small molecule, 18F-TSPF, based on c-Met TKI, as a targeted molecular imaging agent for noninvasive and repeatable detecting c-Met activation status.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age range 18-75 years, open to both male and female participants; 2. Normal hepatic/renal function and cardiac function; 3. Expected survival of at least 12 weeks; 4. Good adherence to follow-up; 5. Presence of at least one measurable target lesion according to RECIST 1.1 criteria; 6. Women of childbearing age (15-49 years) must undergo a pregnancy test within seven days prior to the commencement of the study and test negative; sexually active male and female participants must agree to utilize effective contraception to prevent pregnancy during the study and for three months following the final examination; 7. Patients for whom a clinical physician recommends PET/CT scans for the diagnosis and staging of tumors; 8. Participants must fully understand and voluntarily agree to participate in the study, and must sign an informed consent form. Exclusion Criteria: 1. Severe abnormalities in liver and renal function and blood counts; 2. Patients planning to conceive; 3. Pregnant or lactating women; 4. Individuals unable to lie flat for thirty minutes; 5. Individuals who refuse to participate in this clinical study; 6. Individuals suffering from claustrophobia or other psychiatric disorders; 7. Other situations deemed unsuitable for trial participation by the researchers.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Nuclear Medicine, Fourth Affiliated Hospital of Harbin Medical University Harbin Heilongjiang Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06911697 on ClinicalTrials.gov ↗ ← All trials in China